Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial matching, announces today its newly developed "Hub" aimed to build strategic partnerships with some of the most prominent Just-In-Time (JIT) vendors and provider clinical research teams, looking to facilitate the largest JIT oncology clinical trial network in the world. These vendors and Massive Bio will join forces to provide combined accelerated oncology enrollment solutions and to optimize workflow efficiencies for global pharmaceutical companies. "We understand the current unmet need to bring trials to cancer patients, develop turnkey solutions to enable community-based sites running rapidly to enroll patients, and making this process efficient and at a global scale. We have been working in'stealth mode' over several months to understand the pros-and-cons of leveraging JIT networks. This analysis resulted in Massive Bio's "Hub" development, and its key role in managing a series of JIT Oncology Clinical Trial Networks. This first-in-class Hub is responsible for evaluating market players in the JIT arena, understanding the needs of pharmaceutical companies, and Contract Research Organizations (CROs), assessing the provider networks interested in opening JIT sites, and further enabling clinical research services to perform the highest patient enrollment potential", said Selin Kurnaz, PhD., Co-founder and CEO of Massive Bio.